Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable

Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities